Ensifentrine

A dual inhibitor of phosphodiesterase 3 and 4 used in the treatment of respiratory diseases

{{Drugbox | Verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (R)-3,5-dihydroxy-4-[[2-(3-methoxyphenyl)-2-oxoethyl]amino]cyclohex-2-en-1-one | image = Ensifentrine_structure.png | width = 200 | tradename = | Drugs.com = | CAS_number = 1418013-75-8 | ATC_prefix = | ATC_suffix = | PubChem = 49814553 | ChemSpiderID = 26333216 | UNII = | KEGG = | ChEMBL = 2103870 | C=16 | H=19 | N=1 | O=5 | smiles = COC1=CC=CC(=C1)C(=O)C2=CC(=C(C(=O)C2)O)O }}

Ensifentrine is a novel bronchodilator and anti-inflammatory agent that is currently under investigation for the treatment of chronic obstructive pulmonary disease (COPD) and other respiratory diseases. It is a dual inhibitor of phosphodiesterase (PDE) 3 and 4, which are enzymes involved in the regulation of intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP).

Mechanism of Action

Ensifentrine works by inhibiting the activity of PDE3 and PDE4, leading to an increase in intracellular cAMP and cGMP levels. This results in relaxation of airway smooth muscle, leading to bronchodilation, and also exerts anti-inflammatory effects by reducing the release of pro-inflammatory cytokines and mediators from inflammatory cells.

Clinical Development

Ensifentrine is currently in clinical trials for the treatment of COPD. It has shown promise in improving lung function and reducing symptoms in patients with moderate to severe COPD. The drug is administered via inhalation, which allows for direct delivery to the lungs and minimizes systemic side effects.

Pharmacokinetics

Ensifentrine is rapidly absorbed following inhalation, with peak plasma concentrations occurring within minutes. It is metabolized primarily in the liver and excreted in the urine. The half-life of ensifentrine is approximately 3 to 4 hours, allowing for twice-daily dosing.

Safety and Tolerability

In clinical trials, ensifentrine has been generally well tolerated, with the most common adverse effects being mild to moderate in severity. These include headache, cough, and nasopharyngitis. Serious adverse events are rare.

Potential Benefits

The dual mechanism of action of ensifentrine, combining bronchodilation and anti-inflammatory effects, makes it a promising candidate for the treatment of COPD and potentially other respiratory diseases such as asthma.

Also see

• Chronic obstructive pulmonary disease
• Phosphodiesterase inhibitors
• Bronchodilator
• Asthma